Plain-English translation of NCT06019923 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Researchers are looking for new blood markers that can better predict how ovarian cancer will progress and respond to treatment. Currently, doctors rely on two main blood tests (CA125 and HE4), but these sometimes miss early signs of cancer returning. This study will follow newly diagnosed ovarian cancer patients and collect blood samples at multiple time points to see if other markers in the blood can provide earlier warning signs.
Ovarian cancer is often caught at an advanced stage, and many patients experience recurrence within 1–2 years of treatment. Better monitoring tools could help doctors catch cancer recurrence earlier and personalize treatment plans, which could improve outcomes for patients.
You likely qualify if…
You likely don't qualify if…
You will have blood samples drawn at several points during and after your cancer treatment — likely at diagnosis, during treatment, and at follow-up visits. The researchers will measure various metabolic markers in your blood to track how they change over time and see if they relate to how well your treatment is working. This is an observational study, meaning researchers are watching and measuring rather than testing a new drug or procedure.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China